• Product nameAnti-HLA DR antibody [HL-39]
    See all HLA DR primary antibodies
  • Description
    Mouse monoclonal [HL-39] to HLA DR
  • SpecificityThe antibody binds to a common monomorphic determinant of HLA-DR which is dependent on the association of the heavy and the light chain of HLA-DR molecules.
  • Tested applicationsSuitable for: Flow Cyt, IPmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Tissue/ cell preparation (Human). (Burkitts lymphoma cell line Raji).


  • FormLiquid
  • Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle.
  • Storage bufferPreservative: 15mM Sodium Azide
    Constituents: PBS, pH 7.4
  • Concentration information loading...
  • Purity>95% by SDS-PAGE
  • Purification notesPurified from ascites by protein-A affinity chromatography.
  • ClonalityMonoclonal
  • Clone numberHL-39
  • IsotypeIgG3
  • Research areas


Our Abpromise guarantee covers the use of ab8143 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt
  • Application notesFlow Cyt: Use at an assay dependant concentration.
    IP: Use at an assay dependant dilution.

    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionBinds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
    • Sequence similaritiesBelongs to the MHC class II family.
      Contains 1 Ig-like C1-type (immunoglobulin-like) domain.
    • Post-translational
      Ubiquitinated by MARCH1 or MARCH8 at Lys-244 leading to down-regulation of MHC class II. When associated with ubiquitination of the beta subunit of HLA-DR: HLA-DRB4 'Lys-254', the down-regulation of MHC class II may be highly effective.
    • Cellular localizationCell membrane. Endoplasmic reticulum membrane. Golgi apparatus > trans-Golgi network membrane. Endosome membrane. Lysosome membrane. Late endosome membrane. The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation.
    • Information by UniProt
    • Database links
    • Alternative names
      • DR alpha chain antibody
      • DR alpha chain precursor antibody
      • DRA_HUMAN antibody
      • DRB1 antibody
      • DRB4 antibody
      • Histocompatibility antigen HLA DR alpha antibody
      • HLA class II histocompatibility antigen antibody
      • HLA class II histocompatibility antigen DR alpha chain antibody
      • HLA DR1B antibody
      • HLA DR3B antibody
      • HLA DRA antibody
      • HLA DRA1 antibody
      • HLA DRB1 antibody
      • HLA DRB3 antibody
      • HLA DRB4 antibody
      • HLA DRB5 antibody
      • HLA-DRA antibody
      • HLADR4B antibody
      • HLADRA1 antibody
      • HLADRB antibody
      • Major histocompatibility complex class II DR alpha antibody
      • Major histocompatibility complex class II DR beta 1 antibody
      • Major histocompatibility complex class II DR beta 3 antibody
      • Major histocompatibility complex class II DR beta 4 antibody
      • Major histocompatibility complex class II DR beta 5 antibody
      • MGC117330 antibody
      • MHC cell surface glycoprotein antibody
      • MHC class II antigen DRA antibody
      • MHC II antibody
      • MLRW antibody
      see all

    References for Anti-HLA DR antibody [HL-39] (ab8143)

    This product has been referenced in:
    • Horejsi V  et al. Characterization of seven new monoclonal antibodies against human DR, DR + DP and DQ1 + DQ3 antigens. Tissue Antigens 28:288-97 (1986). Read more (PubMed: 2435017) »

    See 1 Publication for this product

    Product Wall

    Thank you for your patience with me dealing with your enquiry. Regarding ab8143, the originator has informed me that is has not been tested in IHC and they mistakenly told Abcam that it had been. I have updated the online datasheet to reflect this. ...

    Read More

    We have not specifically tested it for blocking in your assay although we suspect it would work since it can also be used for selective removal of cells by complement mediated cytoxicity.

    All the information we have for this product is on the datasheet. It has not yet been tested for cross-reativity with rat, nor has it been tested on wax sections. However, the antibody is suitbale for use in IHC on frozen sections and on sections that ...

    Read More

    IgG (Almost all of our antibodies are IgG's. We stock some IgM's which will be indicated as such on the datasheet)